Global Parkinson’s Disorder Drugs Market – Industry Trends and Forecast to 2031

Parkinson’s Disorder Drugs Market Analysis and Size

Parkinson's disease is a neurodegenerative disorder that primarily affects movement. The drugs are used for managing motor symptoms of Parkinson's disease, including bradykinesia, rigidity, and tremors. Further, the drugs inhibit the breakdown of dopamine in the brain, thereby prolonging its effects and reducing motor symptoms.

Data Bridge Market Research analyses that the global parkinson’s disorder drugs market was valued at USD 4.60 billion in 2023 and is expected to reach USD 12.14 billion by 2031, registering a CAGR of 12.9% during the forecast period of 2024-2031. Decarboxylase Inhibitors accounts for the largest drug class segment in the respective market due to the increased clinical studies and successful launch of several products. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Market Definition

Parkinson's disease is a progressive neurodegenerative disorder that primarily affects movement. It develops gradually, often starting with minor tremors in one hand, and can eventually lead to stiffness or slowing of movement, impaired balance, and coordination problems. Parkinson's disease occurs due to the loss of dopamine-producing cells in a specific region of the brain called the substantia nigra.

Global Parkinson’s Disorder Drugs Market Dynamics

Drivers

• Increasing Prevalence of Parkinson’s Disease

Parkinson's disease is becoming more prevalent globally, largely due to aging populations. As people live longer, the incidence of Parkinson's disease is expected to rise, leading to a larger patient population requiring medication. One of the primary reasons for the rising prevalence of Parkinson's disease is the aging global population. Parkinson's disease is more common in older adults, with the risk of developing the condition increasing with age. As life expectancy increases worldwide, there is a larger population of elderly individuals who are at risk of developing Parkinson's disease. This demographic shift contributes significantly to the growing number of people affected by the condition.

• Patient Advocacy and Support Groups

Patient advocacy organizations and support groups raise awareness about Parkinson's disease, provide resources for patients and caregivers, and advocate for improved access to treatments. These organizations play a vital role in influencing healthcare policies, increasing research funding, and driving innovation in Parkinson's disease drug development.

• Rising Disposable Income

Rising disposable incomes and increasing healthcare expenditure in emerging economies are driving the demand for drugs. As individuals become more financially capable of affording treatments, the demand for parkinson’s disorder drugs is expected to rise, especially in developing regions where access to healthcare is improving.

 Opportunities

• Technological Advancements

Advances in drug delivery systems, such as extended-release formulations and wearable devices for continuous drug delivery, are improving the efficacy, convenience, and patient compliance of Parkinson's disease medications. These innovations contribute to the expansion of the market by addressing the needs of patients and healthcare providers.

• Increasing Awareness and Diagnosis

Growing awareness about Parkinson's disease among healthcare professionals and the general public, coupled with improved diagnostic techniques, leads to earlier detection and diagnosis of the condition. As more patients are diagnosed and treated, the demand for Parkinson's disease medications increases.

Restraints/Challenges

• Limited Efficacy

As Parkinson's disease progresses, the brain's ability to produce and utilize dopamine becomes increasingly impaired. This neurodegenerative process leads to a reduction in the responsiveness of neurons to dopamine replacement therapies, such as levodopa and dopamine agonists. Consequently, the efficacy of these medications may diminish over time, particularly in advanced stages of the disease.

• Side Effects and Complications

Parkinson's disease medications can cause adverse effects, which may limit their use or require careful management. Levodopa therapy can lead to motor fluctuations (such as wearing-off and dyskinesia) and psychiatric symptoms (such as hallucinations and impulse control disorders). Similarly, dopamine agonists may cause side effects such as nausea, dizziness, and impulse control disorders. Managing these side effects while maintaining optimal symptom control can be challenging for patients and healthcare providers.

This global parkinson’s disorder drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global parkinson’s disorder drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In January 2022, Clinical-stage biotech company ABL Bio Inc. collaborated and entered into a worldwide license agreement with Sanofi to develop and commercialize a treatment for Parkinson's disease and other potential indications. The treatment, ABL301, is a preclinical stage bispecific antibody that targets alpha-synuclein and insulin-such as growth factor 1 receptor (IGF1R) with bolstered penetration of the blood-brain barrier

Global Parkinson’s Disorder Drugs Market Scope

The global parkinson’s disorder drugs market is segmented on the basis of drug class, route of administration, distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• Decarboxylase Inhibitors
• Dopamine Agonists
• Monoamine Oxidase Type B (MAO-B) Inhibitor
• Others

Route of Administration

• Oral
• Injection
• Transdermal

Distribution Channel

• Hospitals
• Online Pharmacy
• Others

Global Parkinson’s Disorder Drugs Market Regional Analysis/Insights

The global parkinson’s disorder drugs market is analyzed, and market size information is provided by drug class, route of administration, and distribution channel.

The countries covered in the market report are the U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Poland, Turkey, Switzerland, Netherlands, Hungary, Austria, Norway, Ireland, Lithuania, rest of Europe, China, Japan, India, Australia, South Korea, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, rest of Asia-Pacific, South Africa, Saudi Arabia, U.A.E., Israel, Egypt, Kuwait and rest of the Middle East and Africa.

North America is expected to dominate due to the presence of the largest consumer market with high GDP, favourable reimbursement, and the presence of major market players increased technological advancement in the region.

Asia-Pacific is fastest growing region because of the rapidly aging population, rising prevalence of parkinson driven by changing lifestyles, and rising awareness. Growing aging population and improved diagnosis driving the market expansion in the region.

The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.  

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The global parkinson’s disorder drugs market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global parkinson’s disorder drugs market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on global parkinson’s disorder drugs market. The data is available for historic period 2016-2021.

Competitive Landscape and Global Parkinson’s Disorder Drugs Market Share Analysis

The global parkinson’s disorder drugs market competitive landscape provide details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points are only related to the company's focus on the global parkinson’s disorder drugs market.

Some of the major players operating in the global parkinson’s disorder drugs market are:

• GSK plc (U.K.)
• Boehringer Ingelheim International GmbH (Germany)
• Newron Pharmaceuticals SPA  (U.S.)
• F. Hoffmann-La Roche Ltd (Germany)
• Abbvie Inc. (U.S.)

SKU-70720